Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTR
Optimal post-remission therapy for adolescents and young adults (AYAs) with Ph-negative acute lymphoblastic leukemia (ALL) in first complete remission (CR1) is not established. We compared overall survival (OS), disease-free survival (DFS), relapse, and non-relapse mortality (NRM) for patients recei...
Gespeichert in:
| Veröffentlicht in: | Leukemia 2021-07, Vol.35 (7), p.2076-2085 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2085 |
|---|---|
| container_issue | 7 |
| container_start_page | 2076 |
| container_title | Leukemia |
| container_volume | 35 |
| creator | Wieduwilt, Matthew J. Stock, Wendy Advani, Anjali Luger, Selina Larson, Richard A. Tallman, Martin Appelbaum, Frederick Zhang, Mei-Jie Bo-Subait, Khalid Wang, Hai-Lin Bhatt, Vijaya Raj Dholaria, Bhagirathbhai Eapen, Mary Hamadani, Mehdi Jamy, Omer Prestidge, Tim Pulsipher, Michael Ritchie, David Rizzieri, David Sharma, Akshay Barba, Pere Sandmaier, Brenda M. de Lima, Marcos Kebriaei, Partow Litzow, Mark Saber, Wael Weisdorf, Daniel |
| description | Optimal post-remission therapy for adolescents and young adults (AYAs) with Ph-negative acute lymphoblastic leukemia (ALL) in first complete remission (CR1) is not established. We compared overall survival (OS), disease-free survival (DFS), relapse, and non-relapse mortality (NRM) for patients receiving post-remission therapy on CALGB 10403 to a cohort undergoing myeloablative (MA) allogeneic hematopoietic cell transplantation (HCT) in CR1. In univariate analysis, OS was superior with chemotherapy compared to MA allogeneic HCT (3-year OS 77% vs. 53%,
P
|
| doi_str_mv | 10.1038/s41375-021-01213-5 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8257494</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A667501907</galeid><sourcerecordid>A667501907</sourcerecordid><originalsourceid>FETCH-LOGICAL-c572t-99ed21f6b1cbf8db11e220d276bed211da984307aeb6da3d0acb323a1554aed93</originalsourceid><addsrcrecordid>eNp9Uk1v1DAQDQhES-HIhQOyhIS4pNj5DgektoJSqQgE5WxN4snGxbGD7SzKv8fZXdouQiiHKDPvvZl5eVH0nNFjRtPqjctYWuYxTVhMWcLSOL8fHbKsLOI8z9mD6JBWVRkXdZIdRI-du6Z0aRaPooM0Lau8KpLDe8--TSNaaSxxk13LNSjyS_qejCgkeCvb2PlZIWl7HIzv0cI4k9YMI1gUxBsyzKgMNAq8XCMBpcwKNcqWBAJ4MxqJPny1qBTxFrQbFWgf0EYTqYlRAi0BYRS6FrV3BLQgs5n0KlQnFQqbfb70scbVbkg7eSRqHsbehMFu0Vc4_cBBwqLZSev8ZkmFAWhD3bkw723QBjU76UhnzUDOTi7PTwmjGU03U8N55Ozi9NPV1yfRww6Uw6e791H0_cP7q7OP8eXn84tAi9u8THxc1ygS1hUNa5uuEg1jmCRUJGXRLA0moK6ylJaATSEgFRTaJk1SYHmeAYo6PYrebXXHqRlQLAZYUHy0cgA7cwOS73e07PnKrHmV5GVWZ0Hg9U7Amp8TOs_DrYvXoNFMjic5DX-8LtIF-vIv6LWZbDBkQWVhz6Kk9Ba1AoVc6s6Eue0iyk-Koswpq2kZUMf_QIVHBK9bo7GTob5HeHWH0CMo3zujpiUGbh-YbIGtNc5Z7G7MYJQvqefb1POQer5JPc8D6cVdG28of2IeAOkW4EJLr9De3v4f2d98dhOE</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2548436700</pqid></control><display><type>article</type><title>Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTR</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Wieduwilt, Matthew J. ; Stock, Wendy ; Advani, Anjali ; Luger, Selina ; Larson, Richard A. ; Tallman, Martin ; Appelbaum, Frederick ; Zhang, Mei-Jie ; Bo-Subait, Khalid ; Wang, Hai-Lin ; Bhatt, Vijaya Raj ; Dholaria, Bhagirathbhai ; Eapen, Mary ; Hamadani, Mehdi ; Jamy, Omer ; Prestidge, Tim ; Pulsipher, Michael ; Ritchie, David ; Rizzieri, David ; Sharma, Akshay ; Barba, Pere ; Sandmaier, Brenda M. ; de Lima, Marcos ; Kebriaei, Partow ; Litzow, Mark ; Saber, Wael ; Weisdorf, Daniel</creator><creatorcontrib>Wieduwilt, Matthew J. ; Stock, Wendy ; Advani, Anjali ; Luger, Selina ; Larson, Richard A. ; Tallman, Martin ; Appelbaum, Frederick ; Zhang, Mei-Jie ; Bo-Subait, Khalid ; Wang, Hai-Lin ; Bhatt, Vijaya Raj ; Dholaria, Bhagirathbhai ; Eapen, Mary ; Hamadani, Mehdi ; Jamy, Omer ; Prestidge, Tim ; Pulsipher, Michael ; Ritchie, David ; Rizzieri, David ; Sharma, Akshay ; Barba, Pere ; Sandmaier, Brenda M. ; de Lima, Marcos ; Kebriaei, Partow ; Litzow, Mark ; Saber, Wael ; Weisdorf, Daniel</creatorcontrib><description><![CDATA[Optimal post-remission therapy for adolescents and young adults (AYAs) with Ph-negative acute lymphoblastic leukemia (ALL) in first complete remission (CR1) is not established. We compared overall survival (OS), disease-free survival (DFS), relapse, and non-relapse mortality (NRM) for patients receiving post-remission therapy on CALGB 10403 to a cohort undergoing myeloablative (MA) allogeneic hematopoietic cell transplantation (HCT) in CR1. In univariate analysis, OS was superior with chemotherapy compared to MA allogeneic HCT (3-year OS 77% vs. 53%,
P
< 0.001). In multivariate analysis, allogeneic HCT showed inferior OS (HR 2.00, 95% CI 1.5–2.66,
P
< 0.001), inferior DFS (HR 1.62, 95% CI 1.25–2.12,
P
< 0.001), and increased NRM (HR 5.41, 95% CI 3.23–9.06,
P
< 0.001) compared to chemotherapy. A higher 5-year relapse incidence was seen with chemotherapy compared to allogeneic HCT (34% vs. 23%,
P
= 0.011). Obesity was independently associated with inferior OS (HR 2.17, 95% CI 1.63–2.89,
P
< 0.001), inferior DFS (HR 1.97, 95% CI 1.51–2.57,
P
< 0.001), increased relapse (1.84, 95% CI 1.31–2.59,
P
< 0.001), and increased NRM (HR 2.10, 95% CI 1.37–3.23,
P
< 0.001). For AYA ALL patients in CR1, post-remission therapy with pediatric-style chemotherapy is superior to MA allogeneic HCT for OS, DFS, and NRM.]]></description><identifier>ISSN: 0887-6924</identifier><identifier>ISSN: 1476-5551</identifier><identifier>EISSN: 1476-5551</identifier><identifier>DOI: 10.1038/s41375-021-01213-5</identifier><identifier>PMID: 33785862</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>42/100 ; 631/67/1990/283/2125 ; 692/699/1541/1990/283/2125 ; Acute lymphoblastic leukemia ; Acute lymphocytic leukemia ; Adolescent ; Adolescents ; Adult ; Adults ; Antineoplastic Agents - therapeutic use ; Cancer ; Cancer Research ; Care and treatment ; Chemotherapy ; Cohort Studies ; Comparative analysis ; Critical Care Medicine ; Disease-Free Survival ; Female ; Hematology ; Hematopoietic Stem Cell Transplantation - methods ; Hematopoietic stem cells ; Humans ; Intensive ; Internal Medicine ; Leukemia ; Lymphatic leukemia ; Male ; Medicine ; Medicine & Public Health ; Multivariate analysis ; Oncology ; Patient outcomes ; Pediatrics ; Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy ; Precursor Cell Lymphoblastic Leukemia-Lymphoma - mortality ; Recurrence ; Remission ; Remission (Medicine) ; Remission Induction ; Stem cell transplantation ; Survival ; Teenagers ; Transplantation ; Transplantation Conditioning - methods ; Transplantation, Homologous - methods ; Young Adult ; Young adults ; Youth</subject><ispartof>Leukemia, 2021-07, Vol.35 (7), p.2076-2085</ispartof><rights>The Author(s) 2021</rights><rights>COPYRIGHT 2021 Nature Publishing Group</rights><rights>The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c572t-99ed21f6b1cbf8db11e220d276bed211da984307aeb6da3d0acb323a1554aed93</citedby><cites>FETCH-LOGICAL-c572t-99ed21f6b1cbf8db11e220d276bed211da984307aeb6da3d0acb323a1554aed93</cites><orcidid>0000-0001-5372-510X ; 0000-0002-8568-4522 ; 0000-0003-3030-8420 ; 0000-0003-4078-5001 ; 0000-0003-2371-3655 ; 0000-0003-3281-2081 ; 0000-0002-5414-9228 ; 0000-0002-9767-9739 ; 0000-0003-1038-5197 ; 0000-0002-9816-6302 ; 0000-0002-8607-9404 ; 0000-0001-8078-8579 ; 0000-0001-9168-3203 ; 0000-0003-2513-0533 ; 0000-0003-0015-5902 ; 0000-0003-3364-4366</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1038/s41375-021-01213-5$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1038/s41375-021-01213-5$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>230,314,776,780,881,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33785862$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wieduwilt, Matthew J.</creatorcontrib><creatorcontrib>Stock, Wendy</creatorcontrib><creatorcontrib>Advani, Anjali</creatorcontrib><creatorcontrib>Luger, Selina</creatorcontrib><creatorcontrib>Larson, Richard A.</creatorcontrib><creatorcontrib>Tallman, Martin</creatorcontrib><creatorcontrib>Appelbaum, Frederick</creatorcontrib><creatorcontrib>Zhang, Mei-Jie</creatorcontrib><creatorcontrib>Bo-Subait, Khalid</creatorcontrib><creatorcontrib>Wang, Hai-Lin</creatorcontrib><creatorcontrib>Bhatt, Vijaya Raj</creatorcontrib><creatorcontrib>Dholaria, Bhagirathbhai</creatorcontrib><creatorcontrib>Eapen, Mary</creatorcontrib><creatorcontrib>Hamadani, Mehdi</creatorcontrib><creatorcontrib>Jamy, Omer</creatorcontrib><creatorcontrib>Prestidge, Tim</creatorcontrib><creatorcontrib>Pulsipher, Michael</creatorcontrib><creatorcontrib>Ritchie, David</creatorcontrib><creatorcontrib>Rizzieri, David</creatorcontrib><creatorcontrib>Sharma, Akshay</creatorcontrib><creatorcontrib>Barba, Pere</creatorcontrib><creatorcontrib>Sandmaier, Brenda M.</creatorcontrib><creatorcontrib>de Lima, Marcos</creatorcontrib><creatorcontrib>Kebriaei, Partow</creatorcontrib><creatorcontrib>Litzow, Mark</creatorcontrib><creatorcontrib>Saber, Wael</creatorcontrib><creatorcontrib>Weisdorf, Daniel</creatorcontrib><title>Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTR</title><title>Leukemia</title><addtitle>Leukemia</addtitle><addtitle>Leukemia</addtitle><description><![CDATA[Optimal post-remission therapy for adolescents and young adults (AYAs) with Ph-negative acute lymphoblastic leukemia (ALL) in first complete remission (CR1) is not established. We compared overall survival (OS), disease-free survival (DFS), relapse, and non-relapse mortality (NRM) for patients receiving post-remission therapy on CALGB 10403 to a cohort undergoing myeloablative (MA) allogeneic hematopoietic cell transplantation (HCT) in CR1. In univariate analysis, OS was superior with chemotherapy compared to MA allogeneic HCT (3-year OS 77% vs. 53%,
P
< 0.001). In multivariate analysis, allogeneic HCT showed inferior OS (HR 2.00, 95% CI 1.5–2.66,
P
< 0.001), inferior DFS (HR 1.62, 95% CI 1.25–2.12,
P
< 0.001), and increased NRM (HR 5.41, 95% CI 3.23–9.06,
P
< 0.001) compared to chemotherapy. A higher 5-year relapse incidence was seen with chemotherapy compared to allogeneic HCT (34% vs. 23%,
P
= 0.011). Obesity was independently associated with inferior OS (HR 2.17, 95% CI 1.63–2.89,
P
< 0.001), inferior DFS (HR 1.97, 95% CI 1.51–2.57,
P
< 0.001), increased relapse (1.84, 95% CI 1.31–2.59,
P
< 0.001), and increased NRM (HR 2.10, 95% CI 1.37–3.23,
P
< 0.001). For AYA ALL patients in CR1, post-remission therapy with pediatric-style chemotherapy is superior to MA allogeneic HCT for OS, DFS, and NRM.]]></description><subject>42/100</subject><subject>631/67/1990/283/2125</subject><subject>692/699/1541/1990/283/2125</subject><subject>Acute lymphoblastic leukemia</subject><subject>Acute lymphocytic leukemia</subject><subject>Adolescent</subject><subject>Adolescents</subject><subject>Adult</subject><subject>Adults</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Cancer</subject><subject>Cancer Research</subject><subject>Care and treatment</subject><subject>Chemotherapy</subject><subject>Cohort Studies</subject><subject>Comparative analysis</subject><subject>Critical Care Medicine</subject><subject>Disease-Free Survival</subject><subject>Female</subject><subject>Hematology</subject><subject>Hematopoietic Stem Cell Transplantation - methods</subject><subject>Hematopoietic stem cells</subject><subject>Humans</subject><subject>Intensive</subject><subject>Internal Medicine</subject><subject>Leukemia</subject><subject>Lymphatic leukemia</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Multivariate analysis</subject><subject>Oncology</subject><subject>Patient outcomes</subject><subject>Pediatrics</subject><subject>Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy</subject><subject>Precursor Cell Lymphoblastic Leukemia-Lymphoma - mortality</subject><subject>Recurrence</subject><subject>Remission</subject><subject>Remission (Medicine)</subject><subject>Remission Induction</subject><subject>Stem cell transplantation</subject><subject>Survival</subject><subject>Teenagers</subject><subject>Transplantation</subject><subject>Transplantation Conditioning - methods</subject><subject>Transplantation, Homologous - methods</subject><subject>Young Adult</subject><subject>Young adults</subject><subject>Youth</subject><issn>0887-6924</issn><issn>1476-5551</issn><issn>1476-5551</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp9Uk1v1DAQDQhES-HIhQOyhIS4pNj5DgektoJSqQgE5WxN4snGxbGD7SzKv8fZXdouQiiHKDPvvZl5eVH0nNFjRtPqjctYWuYxTVhMWcLSOL8fHbKsLOI8z9mD6JBWVRkXdZIdRI-du6Z0aRaPooM0Lau8KpLDe8--TSNaaSxxk13LNSjyS_qejCgkeCvb2PlZIWl7HIzv0cI4k9YMI1gUxBsyzKgMNAq8XCMBpcwKNcqWBAJ4MxqJPny1qBTxFrQbFWgf0EYTqYlRAi0BYRS6FrV3BLQgs5n0KlQnFQqbfb70scbVbkg7eSRqHsbehMFu0Vc4_cBBwqLZSev8ZkmFAWhD3bkw723QBjU76UhnzUDOTi7PTwmjGU03U8N55Ozi9NPV1yfRww6Uw6e791H0_cP7q7OP8eXn84tAi9u8THxc1ygS1hUNa5uuEg1jmCRUJGXRLA0moK6ylJaATSEgFRTaJk1SYHmeAYo6PYrebXXHqRlQLAZYUHy0cgA7cwOS73e07PnKrHmV5GVWZ0Hg9U7Amp8TOs_DrYvXoNFMjic5DX-8LtIF-vIv6LWZbDBkQWVhz6Kk9Ba1AoVc6s6Eue0iyk-Koswpq2kZUMf_QIVHBK9bo7GTob5HeHWH0CMo3zujpiUGbh-YbIGtNc5Z7G7MYJQvqefb1POQer5JPc8D6cVdG28of2IeAOkW4EJLr9De3v4f2d98dhOE</recordid><startdate>20210701</startdate><enddate>20210701</enddate><creator>Wieduwilt, Matthew J.</creator><creator>Stock, Wendy</creator><creator>Advani, Anjali</creator><creator>Luger, Selina</creator><creator>Larson, Richard A.</creator><creator>Tallman, Martin</creator><creator>Appelbaum, Frederick</creator><creator>Zhang, Mei-Jie</creator><creator>Bo-Subait, Khalid</creator><creator>Wang, Hai-Lin</creator><creator>Bhatt, Vijaya Raj</creator><creator>Dholaria, Bhagirathbhai</creator><creator>Eapen, Mary</creator><creator>Hamadani, Mehdi</creator><creator>Jamy, Omer</creator><creator>Prestidge, Tim</creator><creator>Pulsipher, Michael</creator><creator>Ritchie, David</creator><creator>Rizzieri, David</creator><creator>Sharma, Akshay</creator><creator>Barba, Pere</creator><creator>Sandmaier, Brenda M.</creator><creator>de Lima, Marcos</creator><creator>Kebriaei, Partow</creator><creator>Litzow, Mark</creator><creator>Saber, Wael</creator><creator>Weisdorf, Daniel</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T5</scope><scope>7T7</scope><scope>7TM</scope><scope>7TO</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-5372-510X</orcidid><orcidid>https://orcid.org/0000-0002-8568-4522</orcidid><orcidid>https://orcid.org/0000-0003-3030-8420</orcidid><orcidid>https://orcid.org/0000-0003-4078-5001</orcidid><orcidid>https://orcid.org/0000-0003-2371-3655</orcidid><orcidid>https://orcid.org/0000-0003-3281-2081</orcidid><orcidid>https://orcid.org/0000-0002-5414-9228</orcidid><orcidid>https://orcid.org/0000-0002-9767-9739</orcidid><orcidid>https://orcid.org/0000-0003-1038-5197</orcidid><orcidid>https://orcid.org/0000-0002-9816-6302</orcidid><orcidid>https://orcid.org/0000-0002-8607-9404</orcidid><orcidid>https://orcid.org/0000-0001-8078-8579</orcidid><orcidid>https://orcid.org/0000-0001-9168-3203</orcidid><orcidid>https://orcid.org/0000-0003-2513-0533</orcidid><orcidid>https://orcid.org/0000-0003-0015-5902</orcidid><orcidid>https://orcid.org/0000-0003-3364-4366</orcidid></search><sort><creationdate>20210701</creationdate><title>Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTR</title><author>Wieduwilt, Matthew J. ; Stock, Wendy ; Advani, Anjali ; Luger, Selina ; Larson, Richard A. ; Tallman, Martin ; Appelbaum, Frederick ; Zhang, Mei-Jie ; Bo-Subait, Khalid ; Wang, Hai-Lin ; Bhatt, Vijaya Raj ; Dholaria, Bhagirathbhai ; Eapen, Mary ; Hamadani, Mehdi ; Jamy, Omer ; Prestidge, Tim ; Pulsipher, Michael ; Ritchie, David ; Rizzieri, David ; Sharma, Akshay ; Barba, Pere ; Sandmaier, Brenda M. ; de Lima, Marcos ; Kebriaei, Partow ; Litzow, Mark ; Saber, Wael ; Weisdorf, Daniel</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c572t-99ed21f6b1cbf8db11e220d276bed211da984307aeb6da3d0acb323a1554aed93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>42/100</topic><topic>631/67/1990/283/2125</topic><topic>692/699/1541/1990/283/2125</topic><topic>Acute lymphoblastic leukemia</topic><topic>Acute lymphocytic leukemia</topic><topic>Adolescent</topic><topic>Adolescents</topic><topic>Adult</topic><topic>Adults</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Cancer</topic><topic>Cancer Research</topic><topic>Care and treatment</topic><topic>Chemotherapy</topic><topic>Cohort Studies</topic><topic>Comparative analysis</topic><topic>Critical Care Medicine</topic><topic>Disease-Free Survival</topic><topic>Female</topic><topic>Hematology</topic><topic>Hematopoietic Stem Cell Transplantation - methods</topic><topic>Hematopoietic stem cells</topic><topic>Humans</topic><topic>Intensive</topic><topic>Internal Medicine</topic><topic>Leukemia</topic><topic>Lymphatic leukemia</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Multivariate analysis</topic><topic>Oncology</topic><topic>Patient outcomes</topic><topic>Pediatrics</topic><topic>Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy</topic><topic>Precursor Cell Lymphoblastic Leukemia-Lymphoma - mortality</topic><topic>Recurrence</topic><topic>Remission</topic><topic>Remission (Medicine)</topic><topic>Remission Induction</topic><topic>Stem cell transplantation</topic><topic>Survival</topic><topic>Teenagers</topic><topic>Transplantation</topic><topic>Transplantation Conditioning - methods</topic><topic>Transplantation, Homologous - methods</topic><topic>Young Adult</topic><topic>Young adults</topic><topic>Youth</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wieduwilt, Matthew J.</creatorcontrib><creatorcontrib>Stock, Wendy</creatorcontrib><creatorcontrib>Advani, Anjali</creatorcontrib><creatorcontrib>Luger, Selina</creatorcontrib><creatorcontrib>Larson, Richard A.</creatorcontrib><creatorcontrib>Tallman, Martin</creatorcontrib><creatorcontrib>Appelbaum, Frederick</creatorcontrib><creatorcontrib>Zhang, Mei-Jie</creatorcontrib><creatorcontrib>Bo-Subait, Khalid</creatorcontrib><creatorcontrib>Wang, Hai-Lin</creatorcontrib><creatorcontrib>Bhatt, Vijaya Raj</creatorcontrib><creatorcontrib>Dholaria, Bhagirathbhai</creatorcontrib><creatorcontrib>Eapen, Mary</creatorcontrib><creatorcontrib>Hamadani, Mehdi</creatorcontrib><creatorcontrib>Jamy, Omer</creatorcontrib><creatorcontrib>Prestidge, Tim</creatorcontrib><creatorcontrib>Pulsipher, Michael</creatorcontrib><creatorcontrib>Ritchie, David</creatorcontrib><creatorcontrib>Rizzieri, David</creatorcontrib><creatorcontrib>Sharma, Akshay</creatorcontrib><creatorcontrib>Barba, Pere</creatorcontrib><creatorcontrib>Sandmaier, Brenda M.</creatorcontrib><creatorcontrib>de Lima, Marcos</creatorcontrib><creatorcontrib>Kebriaei, Partow</creatorcontrib><creatorcontrib>Litzow, Mark</creatorcontrib><creatorcontrib>Saber, Wael</creatorcontrib><creatorcontrib>Weisdorf, Daniel</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing & Allied Health Database</collection><collection>Immunology Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Leukemia</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wieduwilt, Matthew J.</au><au>Stock, Wendy</au><au>Advani, Anjali</au><au>Luger, Selina</au><au>Larson, Richard A.</au><au>Tallman, Martin</au><au>Appelbaum, Frederick</au><au>Zhang, Mei-Jie</au><au>Bo-Subait, Khalid</au><au>Wang, Hai-Lin</au><au>Bhatt, Vijaya Raj</au><au>Dholaria, Bhagirathbhai</au><au>Eapen, Mary</au><au>Hamadani, Mehdi</au><au>Jamy, Omer</au><au>Prestidge, Tim</au><au>Pulsipher, Michael</au><au>Ritchie, David</au><au>Rizzieri, David</au><au>Sharma, Akshay</au><au>Barba, Pere</au><au>Sandmaier, Brenda M.</au><au>de Lima, Marcos</au><au>Kebriaei, Partow</au><au>Litzow, Mark</au><au>Saber, Wael</au><au>Weisdorf, Daniel</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTR</atitle><jtitle>Leukemia</jtitle><stitle>Leukemia</stitle><addtitle>Leukemia</addtitle><date>2021-07-01</date><risdate>2021</risdate><volume>35</volume><issue>7</issue><spage>2076</spage><epage>2085</epage><pages>2076-2085</pages><issn>0887-6924</issn><issn>1476-5551</issn><eissn>1476-5551</eissn><abstract><![CDATA[Optimal post-remission therapy for adolescents and young adults (AYAs) with Ph-negative acute lymphoblastic leukemia (ALL) in first complete remission (CR1) is not established. We compared overall survival (OS), disease-free survival (DFS), relapse, and non-relapse mortality (NRM) for patients receiving post-remission therapy on CALGB 10403 to a cohort undergoing myeloablative (MA) allogeneic hematopoietic cell transplantation (HCT) in CR1. In univariate analysis, OS was superior with chemotherapy compared to MA allogeneic HCT (3-year OS 77% vs. 53%,
P
< 0.001). In multivariate analysis, allogeneic HCT showed inferior OS (HR 2.00, 95% CI 1.5–2.66,
P
< 0.001), inferior DFS (HR 1.62, 95% CI 1.25–2.12,
P
< 0.001), and increased NRM (HR 5.41, 95% CI 3.23–9.06,
P
< 0.001) compared to chemotherapy. A higher 5-year relapse incidence was seen with chemotherapy compared to allogeneic HCT (34% vs. 23%,
P
= 0.011). Obesity was independently associated with inferior OS (HR 2.17, 95% CI 1.63–2.89,
P
< 0.001), inferior DFS (HR 1.97, 95% CI 1.51–2.57,
P
< 0.001), increased relapse (1.84, 95% CI 1.31–2.59,
P
< 0.001), and increased NRM (HR 2.10, 95% CI 1.37–3.23,
P
< 0.001). For AYA ALL patients in CR1, post-remission therapy with pediatric-style chemotherapy is superior to MA allogeneic HCT for OS, DFS, and NRM.]]></abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>33785862</pmid><doi>10.1038/s41375-021-01213-5</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0001-5372-510X</orcidid><orcidid>https://orcid.org/0000-0002-8568-4522</orcidid><orcidid>https://orcid.org/0000-0003-3030-8420</orcidid><orcidid>https://orcid.org/0000-0003-4078-5001</orcidid><orcidid>https://orcid.org/0000-0003-2371-3655</orcidid><orcidid>https://orcid.org/0000-0003-3281-2081</orcidid><orcidid>https://orcid.org/0000-0002-5414-9228</orcidid><orcidid>https://orcid.org/0000-0002-9767-9739</orcidid><orcidid>https://orcid.org/0000-0003-1038-5197</orcidid><orcidid>https://orcid.org/0000-0002-9816-6302</orcidid><orcidid>https://orcid.org/0000-0002-8607-9404</orcidid><orcidid>https://orcid.org/0000-0001-8078-8579</orcidid><orcidid>https://orcid.org/0000-0001-9168-3203</orcidid><orcidid>https://orcid.org/0000-0003-2513-0533</orcidid><orcidid>https://orcid.org/0000-0003-0015-5902</orcidid><orcidid>https://orcid.org/0000-0003-3364-4366</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0887-6924 |
| ispartof | Leukemia, 2021-07, Vol.35 (7), p.2076-2085 |
| issn | 0887-6924 1476-5551 1476-5551 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8257494 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | 42/100 631/67/1990/283/2125 692/699/1541/1990/283/2125 Acute lymphoblastic leukemia Acute lymphocytic leukemia Adolescent Adolescents Adult Adults Antineoplastic Agents - therapeutic use Cancer Cancer Research Care and treatment Chemotherapy Cohort Studies Comparative analysis Critical Care Medicine Disease-Free Survival Female Hematology Hematopoietic Stem Cell Transplantation - methods Hematopoietic stem cells Humans Intensive Internal Medicine Leukemia Lymphatic leukemia Male Medicine Medicine & Public Health Multivariate analysis Oncology Patient outcomes Pediatrics Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy Precursor Cell Lymphoblastic Leukemia-Lymphoma - mortality Recurrence Remission Remission (Medicine) Remission Induction Stem cell transplantation Survival Teenagers Transplantation Transplantation Conditioning - methods Transplantation, Homologous - methods Young Adult Young adults Youth |
| title | Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTR |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T22%3A04%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Superior%20survival%20with%20pediatric-style%20chemotherapy%20compared%20to%20myeloablative%20allogeneic%20hematopoietic%20cell%20transplantation%20in%20older%20adolescents%20and%20young%20adults%20with%20Ph-negative%20acute%20lymphoblastic%20leukemia%20in%20first%20complete%20remission:%20analysis%20from%20CALGB%2010403%20and%20the%20CIBMTR&rft.jtitle=Leukemia&rft.au=Wieduwilt,%20Matthew%20J.&rft.date=2021-07-01&rft.volume=35&rft.issue=7&rft.spage=2076&rft.epage=2085&rft.pages=2076-2085&rft.issn=0887-6924&rft.eissn=1476-5551&rft_id=info:doi/10.1038/s41375-021-01213-5&rft_dat=%3Cgale_pubme%3EA667501907%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2548436700&rft_id=info:pmid/33785862&rft_galeid=A667501907&rfr_iscdi=true |